Home >> Marketplace Archives >> RBCX cleared on Spectra Optia system, 4/14

RBCX cleared on Spectra Optia system, 4/14

Print Friendly, PDF & Email

April 2014—Terumo BCT received FDA 510(k) clearance for red blood cell exchange on the Spectra Optia Apheresis System. This option gives clinicians the flexibility to perform exchange, depletion, and depletion/exchange procedures on the Spectra Optia system and to tailor each procedure for the transfusion management of sickle cell disease in adults and children.

Terumo BCT, 303-205-2546

x

Check Also

FDA clears SN-TPE on Terumo system, 11/13

Terumo BCT has received FDA 510(k) clearance for single-needle therapeutic plasma exchange (SN-TPE) on its Spectra Optia apheresis system. This option gives therapeutic apheresis operators the ability to convert to SN-TPE at the beginning or at any time during the procedure, depending on patient needs.

X